Successful use of levosimendan in a patient during cardiopulmonary bypass

Journal of Cardiac Surgery

Volumn 22, Issue 2, 2007, Pages 153-156

  Iriz, Erkan ^a   Erer, Dilek ^a   Unal, Yusuf ^a   Zor, Hakan ^a   Ozkose, Zerrin ^a   Ozdogan, Mehmet Emin ^a  

^a GAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; DOBUTAMINE; DOPAMINE; LEVOSIMENDAN;

ADULT; ARTICLE; BLOOD PRESSURE; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CARDIOVASCULAR EQUIPMENT; CASE REPORT; CONTINUOUS INFUSION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY OBSTRUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG USE; HEART ATRIUM PRESSURE; HEART FUNCTION; HEART OUTPUT; HEART PROTECTION; HUMAN; INTRAVENOUS CATHETER; LOADING DRUG DOSE; MALE; PATIENT MONITORING;

CARDIAC OUTPUT, LOW; CARDIOPULMONARY BYPASS; CARDIOTONIC AGENTS; CORONARY STENOSIS; HUMANS; HYDRAZONES; INTERNAL MAMMARY-CORONARY ARTERY ANASTOMOSIS; INTRAOPERATIVE COMPLICATIONS; MALE; MIDDLE AGED; MYOCARDIAL STUNNING; PYRIDAZINES; VASODILATOR AGENTS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33847364932     PISSN: 08860440     EISSN: 15408191     Source Type: Journal    
DOI: 10.1111/j.1540-8191.2007.00359.x     Document Type: Article

References (12)

1. Moiseyev VS, Poder P, Andrejevs N, et al: Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. Eur Heart J 2002;23:1422-1432.
2. Nieminen MS, Akkila J, Hasenfuss G, et al: Haemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000;36:1903-1912.
3. Slawsky MT, Colucci WS, Gottlieb SS, et al: Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Study Invest Circul 2000;102:2222-2227.
4. Nijhawan N, Nicolosi AC, Montgomery MW, et al: Levosimendan enhances cardiac performance after cardiopulmonary bypass: A prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999;34:219-228.
5. Kersten JR, Montgomery MW, Pagel PS: Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K (ATP) channels. Anesth Analg 2000;90:5-11.
6. +2 sensitizer levosimendan in human myocardium. Am J Physiol Heart Circ Physiol 2002;282:H131-H137.
7. Hasenfuss G, Pieske B, Castell M, et al: Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation 1998;98:2141-2147.
8. Follath F, Cleland JGF, Just H, et al: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low out put heart failure (the LIDO study): A randomised double blind study. Lancet 2002;360:196-202.
9. Lilleberg J, Nieminen MS, Akkila J, et al: Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 1998;19:660-668.
10. Innes CA, Wagstaff AJ: Levosimendan: A review of its use in the management of acute decompesated heart failure. Drugs 2003;63(23):2651-2671.
11. Kivikko M, Lehtonen L, Colucci WS: Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003;107:81-86.
12. Haikala H, Kaheinen P, Levijoki J: The role of c-AMP and c-GMP dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan. Cardiovasc Res 1997;34:536-546.